| L-DOPA, | L-dopa levodopa, levo-3, 4-dihydroxyphenylalanine |
|---|---|
| Tabs | tablets |
| L-DOPA | Levodopa |
|---|---|
| LD | Levodopa |
| LID | Levodopa-induced dyskinesia |
| carbidopa | <chemical> A peripheral inhibitor of dopa decarboxylase. It is given in parkinsonism along with levodopa to inhibit the conversion of levodopa to dopamine in the periphery, thereby reducing the peripheral adverse effects, increasing the amount of levodopa that reaches the central nervous system, and reducing the dose needed. It has no antiparkinson actions when given alone. Pharmacological action: antiparkinson agents, dopamine agents, enzyme inhibitors. Chemical name: Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)- (12 Dec 1998) |
|---|---|
| levodopa | <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Pharmacological action: antiparkinson agents, dopamine agents. (12 Dec 1998) |
| tablets | Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (12 Dec 1998) |
| tablets, enteric-coated | Tablets coated with material that delays release of the medication until after they leave the stomach. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|